SCHEMBL4032487

SCHEMBL4032487

Oc1ccc(-c2n[nH]c3cc(Cl)ccc23)cc1O

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 3/20 0.61
PDPK1 O15530 1/20 0.53
HSP90AB1 P08238 1/20 0.53
FGFR1 P11362 6/20 0.51
FGFR2 P21802 3/20 0.51
FGFR3 P22607 2/20 0.51
ALOX5 P09917 2/20 0.49
ESR1 P03372 1/20 0.46
CDK4 P11802 3/20 0.46
CCNA2 P20248 3/20 0.46
CCND1 P24385 3/20 0.46
CDK2 P24941 3/20 0.46
CCND3 P30281 3/20 0.46
KDR P35968 3/20 0.46
CHEK1 O14757 2/20 0.46
IDO1 P14902 1/20 0.45
TRPA1 O75762 1/20 0.43
GUSB P08236 1/20 0.43
GSK3B P49841 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4032441 0.84 PDPK1 (0.75) MAP2K4PDPK1HSP90AB1FGFR1FGFR2
SCHEMBL14738828 0.81 MAP2K4 (0.63) MAP2K4PDPK1HSP90AB1FGFR1FGFR2
SCHEMBL4035759 0.79 IDO1 (0.61) MAP2K4PDPK1HSP90AB1FGFR1FGFR2
SCHEMBL4027200 0.78 IDO1 (0.42) MAP2K4PDPK1HSP90AB1FGFR1FGFR2
SCHEMBL4029772 0.78 TRPA1 (0.68) MAP2K4PDPK1HSP90AB1FGFR1FGFR2
SCHEMBL9271850 0.78 MAP2K4 (0.64) MAP2K4PDPK1HSP90AB1FGFR1FGFR2
SCHEMBL25337719 0.77 FGFR1 (0.51) MAP2K4PDPK1HSP90AB1FGFR1FGFR2
SCHEMBL29490953 0.77 FGFR1 (0.51) MAP2K4PDPK1HSP90AB1FGFR1FGFR2
SCHEMBL22801745 0.76 MAP2K4 (1.00) MAP2K4PDPK1HSP90AB1FGFR1FGFR2
SCHEMBL2955244 0.74 MAP2K4 (0.55) MAP2K4PDPK1HSP90AB1FGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542976-B1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH CORP (US) 2009-02-04 EP disclosed
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols WYETH (US) 2007-09-27 US disclosed
US-7241791-B2 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2007-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols INSR, TNNI3, INSRR MAP2K4 793/4885PDPK1 2941/4885HSP90AB1 2737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.